Concepedia

Lack of adverse effect of anti‐tumor necrosis factor‐α biologics in treatment of rheumatoid arthritis: 5 years follow‐up

Ahmed Dewedar, Medhat Shalaby, Sulaiman Al‐Homaid, Ahmed A. Mahfouz, Osama A. Shams, Ahmed Fathy

International Journal of Rheumatic Diseases · 2012 · 23 citations · 19 references

DOI

Abstract

Our results indicate that the use of TNFi therapy appeared to be as safe as traditional DMARDs in treatment of rheumatoid arthritis patients and long-term follow-up with careful examination is essential to pick up any abnormal ADEs.

References

19

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

William G Dixon, Kimme L Hyrich, Kath Watson et al. · Annals of the Rheumatic Diseases · 2009 · 701 citations · Full text

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

James Galloway, Kimme L Hyrich, Louise Mercer et al. · Lara D. Veeken · 2010 · 656 citations · Full text

Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registry

Florence Tubach, Dominique Salmon, Philippe Ravaud et al. · Arthritis & Rheumatism · 2009 · 628 citations · Full text

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

Anja Strangfeld · JAMA · 2009 · 538 citations

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden

Johan Askling, C. Michael Fored, Lena Brandt et al. · Arthritis & Rheumatism · 2005 · 414 citations